OLMA at a glance
Olema Pharmaceuticals, Inc. (OLMA, SEC CIK 1750284) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as September 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Olema Pharmaceuticals, Inc. (OLMA) shares worth $238.8 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Harmon Cyrus on July 24, 2026 of 12,500 shares at $11.71 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 25 funds
- $238.8M · −1 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 7.01 · Item 5.03 · Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Clinical-stage biopharma developing next-generation targeted therapies for ER+ breast cancer, emphasizing oral small molecule endocrine therapies
- New emphasis: Initiated pivotal Phase 3 OPERA-01 trial for palazestrant monotherapy (2023) and Phase 3 OPERA-02 trial with ribociclib combination (2025)
- Strategic shift: Collaboration with Novartis for ribociclib supply, advancing palazestrant as potential endocrine therapy of choice in frontline metastatic breast cancer
- Quantitative highlight: Over 400 patients treated with palazestrant; FDA Fast Track designation granted in July 2022
- Noteworthy: Second product OP-3136 entered clinical development in late 2024 targeting KAT6, with IND clearance and ongoing Phase 1 trial enrollment
Risk Factors
- FDA regulatory risk: reliance on successful OPERA-01 Phase 3 trial results expected fall 2026 for NDA submission and potential FDA approval by late 2027
- Geopolitical/macroeconomic threat: funding and operational risks tied to global economic uncertainty and volatile credit markets impacting capital raises and collaborations
- Supply chain vulnerability: dependence on third-party contract manufacturers (CMOs) for clinical and potential commercial production with no in-house manufacturing
- Competitive risk: Novartis collaboration supplying ribociclib for OPERA-02 trial, with palazestrant competing against established CDK4/6 inhibitors like palbociclib and ribociclib
- Financial risk: accumulated deficit $597.6 million with net losses increasing to $162.5 million in 2025, requiring ongoing substantial capital raises including $237 million net from 2024 private placement
Management Discussion & Analysis
- Revenue and profitability details not disclosed in the provided MD&A excerpt
- Cash flow, capital allocation, buybacks, dividends, and capex information not included
- Forward-looking statements indicating potential risks and uncertainties affecting actual results and events timing
AI summary of the OLMA 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly triggered debt risk: Fourth Amendment added Olema Oncology International Limited as secured guarantor on July 1, 2026
- Most material financial update: outstanding Credit Facility liability reached $3.0 million as of September 30, 2026
- Regulatory risk: FDA may issue a Refusal to File if palazestrant NDA deficiencies preclude substantive review
- Operational risk: OPERA-02 Phase 3 trial combines palazestrant with ribociclib, exposing development to combination-therapy dependencies
- Competitive risk: palazestrant faces approved competitors including ORSERDU, ETCAMAH, and Inluriyo
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product sales
- Net loss $73.6M vs $42.2M YoY, operating margin not disclosed
- R&D largest expense $67.6M, up 69% YoY, driven by OPERA trials and OP-3136
- Cash, equivalents and securities $413.8M; operating cash use $139.0M vs $108.4M
- Runway through mid-2028; OPERA-01 results expected Q1 2027, funding and macroeconomic risks remain
AI summary of the OLMA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Olema Oncology announced a corporate name change on November 12, 2026
- Name change may affect ticker, branding, investor communications and corporate records
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Corporate name changed from Olema Pharmaceuticals, Inc. to Olema Oncology, Inc. effective November 12, 2026
- Name change required no stockholder approval, reducing execution friction
Item 8.01: Other Events
- Principal executive offices relocated effective November 12, 2026
- New headquarters: 365 Oyster Point Blvd., Suite 400, South San Francisco, California
Item EX-99.1: Item EX-99.1
- Corporate name changed to Olema Oncology, Inc. effective November 12, 2026
- Nasdaq listing and ticker unchanged: OLMA on the Nasdaq Global Select Market
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Full results and management commentary available in Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- Q3 net loss widened to $73.6M from $42.2M, reflecting accelerated Phase 3 enrollment and commercialization preparation
- Cash, equivalents and marketable securities declined to $413.8M from $505.4M at December 31, 2025
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Dr. Gorjan Hrustanovic resigned from the Board effective October 14, 2026
- Committee departures included Compensation and Science and Technology committees
AI summaries of OLMA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for OLMA
Don't miss the next OLMA filing
- Alerts as it files. A push when OLMA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut OLMA, by share count.
- Ask anything. An AI agent that reads every OLMA filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| O'Byrne Jason | A | Sep 1, 2026 | 650,000 | - |
| Harmon Cyrus | Sell | Jul 24, 2026 | 12,500 | $11.71 |
| Harmon Cyrus | Sell | Jul 23, 2026 | 12,500 | $11.58 |
| Harmon Cyrus | A | Jun 18, 2026 | 29,500 | - |
| BUTITTA CYNTHIA M | A | Jun 18, 2026 | 29,500 | - |
| Horning Sandra | A | Jun 18, 2026 | 29,500 | - |
| CLARK IAN T | A | Jun 18, 2026 | 29,500 | - |
| Larson Yi | A | Jun 18, 2026 | 29,500 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Operating Income | -$105.0M | -$142.3M | -$178.7M | |
| Net Income | -$96.7M | -$129.5M | -$162.5M | |
| Balance Sheet | ||||
| Total Assets | $276.9M | $451.0M | $533.4M | |
| Equity | $253.9M | $409.0M | $478.6M | |
| ROE | -38.1% | -31.7% | -33.9% | |
| Per Share | ||||
| EPS | $-2.14 | $-2.20 | $-1.87 | |
| Cash Flow | ||||
| Operating CF | -$83.7M | -$104.4M | -$146.7M | |
| CapEx | - | $159K | - | |
Source: XBRL data in Olema Pharmaceuticals, Inc. (OLMA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate OLMA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 25 | $238.8M |
| Q2 2026 | 26 | $508.9M |
| Q1 2026 | 27 | $500.7M |
| Q4 2025 | 25 | $592.9M |
| Q3 2025 | 23 | $198.0M |
| Q2 2025 | 24 | $91.4M |
| Q1 2025 | 21 | $54.7M |
| Q4 2024 | 18 | $59.4M |
- Morgan Stanley+546.3K (+30%)
- BlackRock+466.6K (+7%)
- Ameriprise Financial+312.8K (+37%)
- Vanguard Capital Management LLC+172.0K (+5%)
- Dimensional Fund Advisors+136.3K (+10%)
- T. Rowe Price Group−762.2K (-92%)
- Two Sigma Investments−470.6K (-42%)
- State Street Corp−468.6K (-11%)
- Vanguard Portfolio Management LLC−335.8K (-20%)
- Citadel Advisors LLC−87.9K (-14%)
- Millennium Management+17.3K
- FMR LLC (Fidelity)−12.14M
- U.S. Bancorp−530
Source: 13F-HR filings on SEC EDGAR (aggregated from 189 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
OLMA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 8-K | Nov 10, 2026 | - | Analysis | - |
| 10-Q | Nov 10, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 15, 2026 | - | Analysis | - |
| 4 | Sep 2, 2026 | - | - | - |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 4 | Jul 27, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 8-K | Jun 23, 2026 | - | Analysis | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 8-K | May 26, 2026 | - | Analysis | |
| 8-K | May 21, 2026 | - | Analysis | |
| 8-K | May 12, 2026 | - | Analysis | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | Analysis |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
OLMA SEC filings: frequently asked questions
Which institutions hold OLMA stock?
As of September 30, 2026, the largest Olema Pharmaceuticals, Inc. (OLMA) holders among the 13F filers tracked by SignalX were BlackRock ($62.0 million), State Street Corp ($33.2 million), Vanguard Capital Management LLC ($30.4 million), Morgan Stanley ($20.6 million), Franklin Resources ($17.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the main risks in OLMA's latest 10-K?
In the 10-K filed March 16, 2026, Olema Pharmaceuticals, Inc. (OLMA) flagged: FDA regulatory risk: reliance on successful OPERA-01 Phase 3 trial results expected fall 2026 for NDA submission and potential FDA approval by late 2027. Geopolitical/macroeconomic threat: funding and operational risks tied to global economic uncertainty and volatile credit markets impacting capital raises and collaborations. (AI summary of the Risk Factors section.)
What did OLMA report in its latest 8-K?
Olema Pharmaceuticals, Inc. (OLMA) filed an 8-K on November 12, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 5.03 (Amendments to Articles of Incorporation or Bylaws) and Item 8.01 (Other Events). Olema Oncology announced a corporate name change on November 12, 2026.
What are the latest OLMA SEC filings?
Olema Pharmaceuticals, Inc. (OLMA) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on September 2, 2026.
What is OLMA's SEC CIK number?
Olema Pharmaceuticals, Inc. (OLMA)'s SEC Central Index Key (CIK) is 1750284. EDGAR lists every OLMA filing under that number.
Ask anything about OLMA
The research agent reads OLMA's filings, financials, insider trades and 13F holders, then answers with sources.